Summarized by Masters of Longevity from Fight Aging!.
Partial epigenetic reprogramming via AAV-delivered OSK factors — a news article previewing early human uses, rationale, and monitoring plans.
Key Takeaways
- A few individuals received an 11-gene AAV therapy encoding OSK reprogramming factors administered outside conventional trials.
- Christine Scott received submucosal OSK treatment on March 11, 2026 with doxycycline-controlled expression and cognitive targets.
- KHL Foundation and Triple Helix Science are supporting and monitoring the initiative while reviewing the treatment chronology for prior OSK uses.
